Every month our international team of patent litigation experts provides a practical insight into different aspects of patent litigation in their jurisdiction. We start 2025 with news from Ireland on the current practice in relation to preliminary injunctions.
Ireland has witnessed a significant increase in patent litigation over the past decade, largely benefitting from the adept case management of the Commercial Court. In response to this surge, a dedicated Intellectual Property and Technology list was established within the Commercial Court in 2021, primarily gaining traction in the patent domain.
The dynamic nature of patent disputes, especially in the pharmaceutical sector has led to several precedents in Irish case law. Notably, the Court of Appeal adopted the principle of comity in the case of Norton (Waterford) Limited t/a Teva Pharmaceuticals Ireland v Boehringer Ingelheim Pharma GmbH & Co KG [2022] IECA 58.
The most significant development in Irish patent litigation was the Supreme Court’s decision in MSD v Clonmel [2019] IESC 65, which redefined the test for injunctive relief. This case reimagined the long-standing Campus Oil (Campus Oil v Minister for Industry and Energy (No. 2) [1983] 1 IR 88 criteria focusing on the adequacy of damages and the balance of convenience, alongside whether there was a fair issue to be tried.
Prior to this case, the High Court had denied a preliminary injunction sought by the patentee in Gilead v Mylan [2017] IEHC 666, but the revised test from MSD v Clonmel marked a turning point.
In its seminal judgment, the Supreme Court set out an 8-step process for courts to consider when deciding on preliminary injunctions: